EuroPCR 2019 | Stent Firehawk Continues to Show Good Results at 2 Years vs. Xience

This device, an abluminal groove-filled biodegradable-polymer sirolimus-eluting stent manufactured in China, showed very similar efficacy and safety to the “gold standard” everolimus eluting Xience at 2-year follow up, according to the TARGET outcomes, presented yesterday at the EuroPCR 2019 and simultaneously published in J Am Coll Cardiol Intv.

EuroPCR 2019 | Stent Firehawk continúa con sus buenos resultados a 2 años frente al Xience

The device, which is manufactured in China and received CE Mark approval in 2015, has recessed abluminal grooves that allow controlled release of sirolimus (90% of the drug is released over the first 90 days). Its polymer degrades within 6 to 9 months. Xience, meanwhile, has a durable polymer and releases nearly all of its everolimus within 120 days.

Firehawk is designed to reduce drug concentration and drug burden in the vessel wall, releasing only the necessary from the abluminal wall.

Firehawk one-year outcomes were presented at this same event in 2018, and now the 2 year-outcomes confirm the good news.


Lea también: EuroPCR 2019 | BASKET-SMALL 2: Drug-Coated Balloons vs. DES in Small Vessels.


The TARGET was a multicenter non-inferiority study carried out at 21 centers in 10 European countries that included 1653 all comers with symptomatic coronary artery disease or asymptomatic but with objective evidence of ischemia to receive the Firehawk (Shanghai MicroPort Medical Group) or the Xience (Abbott Vascular).

Nearly 9% of the population was treated in the context of STEMI. 94.5% of patients completed follow-up or died during this period.

Primary combined end point of target vessel failure (cardiac death, target vessel MI or ischemia driven revascularization) resulted practically identical between devices (Firehawk 8,7% vs Xience 8.6%), as were the individual components.

Patient oriented end points (all cause death, any MI or any revascularization) occurred in 19.3% of the Firehawk cohort and 17.8% of the Xience cohort (p=0.46).


Lea también: EuroPCR 2019 | Intravascular Imaging Almost Indispensable for Planning an Angioplasty.


Definite/probable thrombosis was a rare event and occurred in 0.4% of patients receiving the Firehawk vs. 0.9% of patients receiving the Xience after one year (p=0.34).

There is no evidence of clinical advantage with the Chinese device (as all studies on resorbable vs. durable polymers have shown), though patients will be followed up to 5 years.

With practically identical results and lower costs, the Firehawk aims at entering more markets and becoming a real competitor against the classic stents.

target-presentacion-europcr

Original Title: Two-year clinical outcomes of an abluminal groove-filled biodegradable polymer sirolimus-eluting stent compared to a durable polymer everolimus-eluting stent.

Reference: Xu B et al. J Am Coll Cardiol Intv. 2019; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....